DAWN
Day One Biopharmaceuticals Inc.
Company Overview
| Mkt Cap | $879.93M | Price | $8.52 |
| Volume | 2.93M | Change | +2.77% |
| P/E Ratio | -9.2 | Open | $8.31 |
| Revenue | $131.2M | Prev Close | $8.29 |
| Net Income | $-95.5M | 52W Range | $5.64 - $14.46 |
| Div Yield | N/A | Target | $23.00 |
| Overall | 55 | Value | 60 |
| Quality | -- | Technical | 50 |
No chart data available
About Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Latest News
Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI) and Day One Biopharmaceuticals (DAWN)
Day One Biopharmaceuticals Reports Strong Q3 2025 Growth
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Day One Biopharmaceuticals (DAWN)
Day One Biopharmaceuticals’ Phase 3 Trial: A Potential Game Changer in Pediatric Glioma Treatment
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DAWN | $8.52 | +2.8% | 2.93M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Day One Biopharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW